Awad Kheloud, Jaam Myriam, Awaisu Ahmed, Stewart Derek, Rathore Hassaan Anwer, Abdul Hadi Muhammad
Department of Clinical Pharmacy and Practice, College of Pharmacy, QU Health, Qatar University, Doha, Qatar.
Department of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, Doha, Qatar.
J Pharm Policy Pract. 2024 Feb 7;17(1):2305770. doi: 10.1080/20523211.2024.2305770. eCollection 2024.
Pharmacists can play an important role in the fight against tuberculosis (TB) through optimising medication use and safety, promoting adherence to anti-TB drugs, and providing patient education. Limited evidence is available on the effectiveness of pharmacist's interventions on health outcomes in patients with pulmonary TB. This systematic review aims to assess the effectiveness of pharmaceutical care interventions in the management of pulmonary TB.
English language studies assessing the impact of pharmaceutical care interventions in TB management were searched across three electronic databases (PubMed, Embase, Cochrane), a RCT registry ClinicalTrial.gov, a peer-reviewed journal 'The Lancet Infectious Diseases', and the references of retrieved articles. Interventions delivered by pharmacists alone or as part of multidisciplinary teams were included in the review. Data were extracted using the modified Cochrane EPOC standardised data collection tool. The Cochrane Risk of Bias 2 and the NIH quality assessment tools were used to assess the risk of bias among included studies. Data were synthesised narratively. (PROSPERO Protocol Registration CRD42022325771).
Thirteen studies, including two randomised controlled trials (RCTs) with a total of 3886 patients were included. Many of the included studies had a high risk of bias and lacked cohert reporting of treatment outcomes. The most common pharmaceutical care interventions were education and counselling regarding adverse drug reactions and resolution of drug-related problems. Five studies showed a relatively high TB completion rate yet only one study reached the targeted treatment success goal of (>90%).
The current evidence suggests that pharmaceutical care interventions can potentially improve treatment outcomes among patients with pulmonary TB. However, no definitive conclusion can be drawn given the low methodological quality of the included studies and lack of long-term follow-up data. Well-designed RCTs with careful attention to study methodology, standardised outcomes assessment aligned with the World Health Organization's guidelines are warranted to guide future practice and policy.
药剂师可通过优化药物使用与安全性、促进抗结核药物的依从性以及提供患者教育,在抗击结核病(TB)中发挥重要作用。关于药剂师干预对肺结核患者健康结局有效性的证据有限。本系统评价旨在评估药学服务干预在肺结核管理中的有效性。
在三个电子数据库(PubMed、Embase、Cochrane)、随机对照试验注册库ClinicalTrial.gov、同行评审期刊《柳叶刀传染病学》以及检索文章的参考文献中,检索评估药学服务干预对结核病管理影响的英文研究。由药剂师单独或作为多学科团队一部分实施的干预措施纳入本评价。使用改良的Cochrane EPOC标准化数据收集工具提取数据。采用Cochrane偏倚风险2和美国国立卫生研究院质量评估工具评估纳入研究的偏倚风险。对数据进行叙述性综合分析。(国际前瞻性系统评价注册库协议注册号CRD42022325771)。
纳入13项研究,包括两项随机对照试验(RCT),共3886例患者。许多纳入研究存在较高偏倚风险,且缺乏对治疗结局的连贯报告。最常见的药学服务干预是关于药物不良反应的教育和咨询以及解决药物相关问题。五项研究显示结核完成率相对较高,但只有一项研究达到了(>90%)的目标治疗成功目标。
目前证据表明,药学服务干预可能改善肺结核患者的治疗结局。然而,鉴于纳入研究的方法学质量较低且缺乏长期随访数据,无法得出明确结论。需要精心设计的RCT,仔细关注研究方法,采用与世界卫生组织指南一致的标准化结局评估,以指导未来的实践和政策。